X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    NHS Acquires Potentially Lifesaving Breast Cancer Medication

    Transfusion of The First Patients Lab-Grown Blood Cells

    Bispecific Cancer Drugs, Gene Therapy Advances At Next ASH

    First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

    First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

    $2 Million Gene Therapy Might Become The Standard In The US

    $2 Million Gene Therapy Might Become The Standard In The US

    Cancer Medicine Prices Jump 53% In Five Years In The U.S

    Food And Drug Administration User Fee Has Been Reauthorized

    Cancer Clinical Trials Get A Brand New Platform In Melbourne

    Report Indicates UK £62bn Behind In Global R&D Investment

    Report Indicates UK £62bn Behind In Global R&D Investment

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    NHS Acquires Potentially Lifesaving Breast Cancer Medication

    Transfusion of The First Patients Lab-Grown Blood Cells

    Bispecific Cancer Drugs, Gene Therapy Advances At Next ASH

    First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

    First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

    $2 Million Gene Therapy Might Become The Standard In The US

    $2 Million Gene Therapy Might Become The Standard In The US

    Cancer Medicine Prices Jump 53% In Five Years In The U.S

    Food And Drug Administration User Fee Has Been Reauthorized

    Cancer Clinical Trials Get A Brand New Platform In Melbourne

    Report Indicates UK £62bn Behind In Global R&D Investment

    Report Indicates UK £62bn Behind In Global R&D Investment

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Drug Development Research & Development

Time is of the essence for millions living with ‘neglected’ lung disease

Yuvraj_pawp by Yuvraj_pawp
19th November 2015
in Research & Development

Your Time campaign calls for earlier action in COPD

WHO expects COPD to be the third leading cause of death worldwide by 2030 – exceeded only by heart disease and stroke

By the time most people know they have COPD, around 50% of their lung function2,3 is lost and daily life can be negatively impacted

Earlier, optimal management can slow the progress of COPD4 and could help patients live a better life for longer

Ingelheim, Germany, 17th November, 2015 – Boehringer Ingelheim today announced the launch of the Your Time campaign – a worldwide call to raise public awareness of chronic obstructive pulmonary disease (COPD) and the importance of acting now. By diagnosing and optimally managing the disease earlier it’s still possible to make a real difference to patients’ lives. Despite the disease affecting 210 million people worldwide5 and being responsible for twice as many deaths as diabetes,6 it is little known or talked about. By the time most people know they have COPD, they will have already lost around 50% of their lung function2,3 – and urgent, optimal management is necessary. Identifying and optimally managing COPD in the early stages has the potential to slow the progression of the disease4 and may give patients the best opportunity of living a better life for longer. The Your Time campaign echoes the context of this year’s World COPD Day (18 November 2015), organised by GOLD* around the theme “It’s Not Too Late”.

“COPD has significant physical and emotional impacts on patients. Both patients and healthcare professionals need to be alert to the early signs of COPD, when much of the damage to a patient’s lungs occurs. When COPD is first suspected, I would like to see the same sense of urgency as we give to the first signs of cancer,” said Dr. Richard Russell, consultant respiratory physician, Lymington New Forest Hospital, Hampshire and Senior Clinical Researcher, University of Oxford.

“Increasing awareness of the condition, and the need to tackle it early, is both urgent and important. Effective, early management could mean that people with COPD are more able to maintain a normal active life – such as walking upstairs without stopping, going out to socialise with family and friends or finding it easier to continue doing the things that they enjoy,” Dr Russell continued.

COPD is not only a personal challenge but also a growing challenge for public health. It is the only major cause of death where incidence is increasing and the World Health Organization (WHO) predict that by 2030 COPD will be the 3rd leading cause of death worldwide1 – exceeded only by heart diseases and stroke. In Europe, the annual costs of healthcare and lost productivity due to COPD are estimated as €48.4 billion euros.

Find out more about the Your Time campaign at http://www.yourtimeCOPD.com

Making Twitter #COUGH

As part of a drive to raise awareness of COPD and the importance of identifying and diagnosing the disease early, on World COPD Day 2015 Boehringer Ingelheim is aiming to make Twitter #COUGH. As the world #COUGHs the hashtag will produce a noisy spike in Tweets, simulating the sound wave of a COPD sufferer’s chronic cough – a key symptom of the disease.

Look out for and share Tweets with #COUGH this World COPD Day, 18 November to raise awareness and encourage people to act now on COPD.

About COPD

COPD is a progressive, treatable but incurable lung disease. For people with COPD, lung damage causes breathlessness that makes it difficult to keep active and participate in life to the extent they would love to. This can lead to a ‘downward spiral’ of worsening symptoms and even further inactivity,9 contributing to an increased risk of disability and death.10 Optimal management to maintain patients’

quality of life has been shown to significantly reduce their likelihood of having an exacerbation (sudden worsening) of COPD symptoms, or being admitted to hospital.

European COPD Coalition: Call to Action on COPD

Boehringer Ingelheim supports the European COPD Coalition’s Call to Action on COPD which seeks political impetus to put in place an EU COPD framework to improve the health and quality of life of European citizens, including persons at risk of, or affected by, COPD.

To find out more and sign the petition visit www.copdcoalition.eu

Previous Post

Boehringer Ingelheim partners with leading scientific institutions in inflammatory bowel disease research

Next Post

Boehringer Ingelheim will invest 11 billion euros in Research and Development in the next five years to accelerate the discovery of next generation medical breakthroughs

Related Posts

News

Cancer Medicine Prices Jump 53% In Five Years In The U.S

3rd November 2022
Report Indicates UK £62bn Behind In Global R&D Investment
News

Report Indicates UK £62bn Behind In Global R&D Investment

3rd November 2022
News

Once More, M&As In Biotechechnology Industry Are Thriving

2nd November 2022
DNA
News

Ancient Viral DNA Guards Against Infections In Human Genome

31st October 2022
News

Omicron Subvariants Withstand Essential Antibody Treatments

31st October 2022
As Medical Uses Cope Up, Genomic Studies Reap Scale Benefits
News

Research And Development In UK Falls Behind Other Nations

28th October 2022
Next Post

Boehringer Ingelheim will invest 11 billion euros in Research and Development in the next five years to accelerate the discovery of next generation medical breakthroughs

Latest News

FDA Approvals

NHS Acquires Potentially Lifesaving Breast Cancer Medication

9th November 2022
Clinical Trials

Transfusion of The First Patients Lab-Grown Blood Cells

9th November 2022
Clinical Trials

Bispecific Cancer Drugs, Gene Therapy Advances At Next ASH

8th November 2022
India Seeks Better Pharma Market Access In The UK: Official
Facilities & Operation

India Seeks Better Pharma Market Access In The UK: Official

8th November 2022
First Virtual Drug Study Tests 2 Likely Alzheimer Therapies
Clinical Trials

First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

7th November 2022
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In